Research programme: antibody-drug conjugates - MedImmune/Seattle Genetics
Latest Information Update: 11 Aug 2009
At a glance
- Originator MedImmune
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 11 Aug 2009 Preclinical development is ongoing in USA
- 05 Nov 2007 MedImmune has exercised its option to obtain an exclusive license to a second antigen target under the antibody-drug congugate collaboration with Seattle Genetics
- 19 Jun 2007 MedImmune has been acquired by AstraZeneca